Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2014

Yu Ziyang, Cai Changmeng, Gao Shuai, Simon Nicholas I, Shen Howard C, Balk Steven P

Abstract excerpt

PURPOSE: Galeterone inhibits the enzyme CYP17A1 and is currently in phase II clinical trials for castration-resistant prostate cancer (CRPC). Galeterone is also a direct androgen receptor (AR) antagonist and may enhance AR degradation. This study was undertaken to determine the molecular basis for AR effects and their therapeutic potential. EXPERIMENTAL DESIGN: Effects of galeterone on AR expression and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Androstadienes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Chromatin Immunoprecipitation

Share to Mutant Proteins

Share to Prostatic Neoplasms, Castration-Resistant

Share to Proteolysis

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 24874833
DOI: 10.1158/1078-0432.CCR-14-0292
PMCID: PMC4119496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.PMID 24874833Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.Semantic proximity Read ↗

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survivalSemantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancerSemantic proximity Read ↗

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.Semantic proximity Read ↗

Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.Semantic proximity Read ↗

Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.Semantic proximity Read ↗

Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamideSemantic proximity Read ↗

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor PyrviniumSemantic proximity Read ↗

Ligand Binding Prolongs Androgen Receptor Protein Half-Life by Reducing its DegradationSemantic proximity Read ↗

A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.